MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.10
-0.05
-0.41%
Closed 16:14 06/01 EDT
OPEN
12.19
PREV CLOSE
12.15
HIGH
12.74
LOW
12.06
VOLUME
488.10K
TURNOVER
--
52 WEEK HIGH
27.15
52 WEEK LOW
7.52
MARKET CAP
802.81M
P/E (TTM)
-3.6646
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GOSS stock price target is 27.88 with a high estimate of 36.00 and a low estimate of 22.00.

EPS

GOSS News

More
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
ACCESSWIRE · 7h ago
SHAREHOLDER ALERT: GOSS R SRNE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
ACCESSWIRE · 13h ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS
Newsfile · 20h ago
Gossamer Bio Announces Participation in Upcoming Investor Conferences
Business Wire · 23h ago
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GOSS, GSX and IQ
ACCESSWIRE · 1d ago
GOSS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020
NEW YORK, NY / ACCESSWIRE / May 31, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the ...
ACCESSWIRE · 1d ago
2-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Newsfile · 1d ago
FINAL DEADLINE: ROSEN, A TRUSTED AND RANKED FIRM, Encourages Gossamer Bio, Inc. Investors with Losses to Contact Firm Before Important June 2 Deadline in Securities Class Action- GOSS
ACCESSWIRE · 2d ago

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About GOSS

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program. GB001 is an oral antagonist of prostaglandin D2 receptor 2, or DP2, is being developed for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor is being developed for the treatment of pulmonary arterial hypertension. GB004 is being developed for Inflammatory Bowel Disease (IBD). GB1275 is a CD11b agonist.
More

Webull offers kinds of Gossamer Bio Inc stock information, including NASDAQ:GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions.